BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20827794)

  • 1. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
    Steffens DC; Nelson JC; Eudicone JM; Andersson C; Yang H; Tran QV; Forbes RA; Carlson BX; Berman RM
    Int J Geriatr Psychiatry; 2011 Jun; 26(6):564-72. PubMed ID: 20827794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
    Stewart TD; Hatch A; Largay K; Sheehan JJ; Marler SV; Berman RM; Nelson JC
    J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
    Nelson JC; Rahman Z; Laubmeier KK; Eudicone JM; McQuade RD; Berman RM; Marcus RN; Baker RA; Sheehan JJ
    CNS Spectr; 2014 Dec; 19(6):528-34. PubMed ID: 24642260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
    Nelson JC; Thase ME; Bellocchio EE; Rollin LM; Eudicone JM; McQuade RD; Marcus RN; Berman RM; Baker RA
    Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
    Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
    J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.
    Casey DE; Laubmeier KK; Eudicone JM; Marcus R; Berman RM; Rahman Z; Sheehan J
    Int J Clin Pract; 2014 Nov; 68(11):1301-8. PubMed ID: 25196314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
    Wisniewski SR; Chen CC; Kim E; Kan HJ; Guo Z; Carlson BX; Tran QV; Pikalov A
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).
    Kamijima K; Higuchi T; Ishigooka J; Ohmori T; Ozaki N; Kanba S; Kinoshita T; Koyama T;
    J Affect Disord; 2013 Dec; 151(3):899-905. PubMed ID: 24074484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
    Fava M; Mischoulon D; Iosifescu D; Witte J; Pencina M; Flynn M; Harper L; Levy M; Rickels K; Pollack M
    Psychother Psychosom; 2012; 81(2):87-97. PubMed ID: 22286203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.
    Jon DI; Kim DH; Seo HJ; Kwon YJ; Kim MD; Yang JC; Suh HS; Min KJ; Pae CU; Bahk WM
    Clin Neuropharmacol; 2013; 36(5):157-61. PubMed ID: 24045606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive aripiprazole for depression: predictive value of early assessment.
    Muzina DJ; Chambers JS; Camacho TA; Eudicone JM; Forbes RA; Berman RM; Baker RA
    Am J Manag Care; 2011 Dec; 17(12):793-801. PubMed ID: 22216750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial.
    Mazza M; Squillacioti MR; Pecora RD; Janiri L; Bria P
    Expert Opin Pharmacother; 2008 Dec; 9(18):3145-9. PubMed ID: 19040335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
    Fava M; Wisniewski SR; Thase ME; Baker RA; Tran QV; Pikalov A; Yang H; Marcus RN; Berman RM
    J Clin Psychopharmacol; 2009 Aug; 29(4):362-7. PubMed ID: 19593176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
    Simon JS; Nemeroff CB
    J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
    Thase ME; Jonas A; Khan A; Bowden CL; Wu X; McQuade RD; Carson WH; Marcus RN; Owen R
    J Clin Psychopharmacol; 2008 Feb; 28(1):13-20. PubMed ID: 18204335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.